37 results
6-K
EX-99.1
ACIU
AC Immune SA
21 May 24
Current report (foreign)
8:00am
their shares through their broker or bank (“Beneficial Owners”), should receive or request these materials through their broker or bank and should
6-K
EX-99.1
ACIU
AC Immune SA
13 May 24
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
6:00am
Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs
6-K
EX-99.1
ACIU
AC Immune SA
24 May 23
Invitation to the Annual General Meeting 2023 To the Shareholders of AC Immune SA
4:07pm
receive or request these materials through their broker or bank and should be able to vote on the broker/bank portal. Voting Shareholders may vote
6-K
EX-99.1
ACIU
AC Immune SA
25 May 22
Notice of the Annual General Meeting 2022 To the Shareholders of AC Immune SA
4:29pm
Computershare. Shareholders who hold their shares through their broker or bank (“Beneficial Owners”), should receive these materials through their broker
6-K
EX-99.3
yytijqu ki
22 Mar 22
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
7:03am
6-K
EX-99.2
donj7s
22 Mar 22
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
7:03am
6-K
EX-99.1
kzuazduw
16 Mar 22
AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference
7:51am
6-K
EX-99.1
onjl5n9jk890o
7 Oct 21
Notice of the Extraordinary General Meeting (EGM) of 29 October 2021 To the Shareholders of AC Immune SA 1
7:27am
6-K
EX-10.1
62pxt
4 Aug 21
Current report (foreign)
7:21am
6-K
EX-99.1
hu5bagzxyhuu
21 May 21
Notice of the Annual General Meeting 2021 To the Shareholders of AC Immune SA 1
8:55am
424B5
13jn6za
5 May 21
Prospectus supplement for primary offering
4:47pm
6-K
EX-99.1
hvqob9 sm
28 Apr 21
Current report (foreign)
7:11am
6-K
0im43m0qdd2beb
23 Mar 21
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
9:06am
6-K
EX-99.3
kxijzovi3aqb16lr
23 Mar 21
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
9:06am
6-K
EX-99.2
6c6v74xrev
23 Mar 21
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
9:06am
6-K
EX-99.1
v44ex6c2i6oh13ioepjn
13 Nov 20
Current report (foreign)
8:03am
6-K
EX-99.1
ytela6k2i
5 Aug 20
Current report (foreign)
7:29am